在Apa-RP研究中，皮疹管理指南对接受阿帕鲁胺治疗的高危局限性前列腺癌患者的影响。
Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study.
作者信息
Shore Neal, Hafron Jason, Saltzstein Daniel, Bhaumik Amitabha, Aggarwal Pankaj, Phillips Jennifer, McGowan Tracy
机构信息
Carolina Urologic Research Center, Myrtle Beach, SC, USA.
Michigan Institute of Urology, West Bloomfield, MI, USA.
出版信息
Prostate Cancer Prostatic Dis. 2024 Jul 5. doi: 10.1038/s41391-024-00858-4.
BACKGROUND/OBJECTIVES: Based on the SPARTAN and TITAN studies, apalutamide is approved for patients with nonmetastatic castration-resistant and metastatic castration-sensitive prostate cancer. Skin rash was a common adverse reaction across indications. We hypothesized that earlier identification and intervention could improve rash outcomes.
SUBJECTS/METHODS: A prespecified rash management guide outlining recommended skin care practices was provided to all patients enrolled in Apa-RP (NCT04523207). Rash-related safety data from Apa-RP were compared descriptively with data from SPARTAN and TITAN.
RESULTS
Patients in Apa-RP experienced improved rash-related outcomes vs those in SPARTAN and TITAN.
CONCLUSIONS
Increased vigilance and proactive management may reduce the incidence, severity, and duration of rash during apalutamide treatment.
背景/目的：基于SPARTAN和TITAN研究，阿帕鲁胺被批准用于非转移性去势抵抗性和转移性去势敏感性前列腺癌患者。皮疹是各适应症中常见的不良反应。我们假设早期识别和干预可以改善皮疹结局。
受试者/方法：向所有参与Apa-RP（NCT04523207）的患者提供了一份预先制定的皮疹管理指南，概述了推荐的皮肤护理措施。将Apa-RP中与皮疹相关的安全性数据与SPARTAN和TITAN的数据进行描述性比较。
结果
与SPARTAN和TITAN中的患者相比，Apa-RP中的患者皮疹相关结局有所改善。
结论
提高警惕和积极管理可能会降低阿帕鲁胺治疗期间皮疹的发生率、严重程度和持续时间。
Zotero 插件